Jun 30, 2008 - Flurizan Fails to Achieve Significance on Either Co-Primary Endpoint; Company Has Decided to Discontinue Its Development of Flurizan - Myriad Genetics, Inc. (NASDAQ: MYGN) announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease. The study did not achieve statistical significance on either of its primary endpoints -- cognition and activities of daily living... Myriad Genetics' Press Release -
Friday, July 11, 2008
Myriad Genetics : Results of U.S. Phase 3 Trial of Flurizan in Alzheimer's Disease
Jun 30, 2008 - Flurizan Fails to Achieve Significance on Either Co-Primary Endpoint; Company Has Decided to Discontinue Its Development of Flurizan - Myriad Genetics, Inc. (NASDAQ: MYGN) announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease. The study did not achieve statistical significance on either of its primary endpoints -- cognition and activities of daily living... Myriad Genetics' Press Release -
